CD38 and plasma cell myeloma: The lethality of anti-CD38 antibodies to myeloma cells is due to a combination of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) [13].